About BETAMI
|
|
Beta-blockers have been part of the treatment after heart attacks since the early 1980s, where three studies showed a beneficial effect on survival. However, since then, the treatment of the heart attack patient has changed drastically, both in the acute course (revascularization) and afterwards to prevent further problems (secondary prevention).
It is important to reassess beta-blockers' place in treating heart attacks. Do they have the beneficial effect anymore considering the treatment options now available? BETAMI will repeat the scientific trial that was carried out over 30 years ago, but with today's standard of care. |
Study design
BETAMI aims to include 10.000 patients with a 2-year follow-up for clinical endpoints
|
"Do All Patients Need β-blockers After a Heart Attack?” Abbasi J. JAMA 2018
BETAMI
It is vital to provide the right patient with the right treatment at all times. Often, research aims to provide patients with new treatments to improve outcome. In this study, the aim is to verify an existing treatment
In other words: 'Do we really need it?' BETAMI is a national study conducted at major hospitals in Norway This study is important to future patients |
|